CaReMe: Bringing Close Collaborative Care for Cardiovascular, Renal and Metabolic Patients

Vice President, CVRM, Global Medical Affairs, AstraZeneca

WRITTEN BY

Danilo Verge, Vice President, CVRM, Global Medical Affairs, AstraZeneca

As science continues to uncover commonalities between cardiovascular, renal and metabolism (CVRM), we are focusing on addressing overlapping disease areas and risk factors, instead of treating each condition individually.

Cardiovascular, renal and metabolic diseases are killing over 20 million people each year1–3. Together, these three disease areas are the leading causes of death across the globe2. Cardiovascular deaths could be caused by a metabolic or renal complication, which is common. For example, if you are an adult in the US with diabetes, you could be 1.8 times more likely to be hospitalised for heart attacks than adults without diabetes.4 Or if you develop chronic kidney disease, evidence suggests you are more likely to have a history of hypertension 10 to 30 years before disease onset5 than those who do not develop CKD.

Our CaReMe approach aims to see and embrace the full cardio-renal and metabolic picture. We recognise the patient as one, across diseases, and we care for the full person. Our focus is on delivering concrete outcomes and improving patient lives and we make it our responsibility to help healthcare professionals connect the dots, evolve their clinical practices and provide potentially life-saving treatment to patients. Our approach will also allow the sharing of knowledge between specialties and with primary care physicians, which in turn will improve foresight into the overlapping conditions.

We know this is going to be a tough task, so we are actively investing in broader and stronger partnerships with academic institutions and research organisations. Furthermore, we are looking to use close collaboration with cardiovascular, renal and metabolic experts from around the world, to help us pave the way for clinical practice evolution.

By taking risks in research, science and investigation we systematically study compounds across diseases and combinations of our assets – striving to create uncharted pathways of clinical exploration. Clinical research and real-world settings not only help us evaluate CVRM connections and measure patient outcomes, but also understand how the deterioration of one condition could adversely affect the others.

We now have more than 25 therapies and therapy combinations across the various CVRM diseases in our early-to-late stage pipeline. All of which are inspired by our CaReMe sciences and thanks to which we seek to help HCPs treat life-combatting conditions such as CKD, ACS, and CHF. But we want to go beyond the treatment, by building and supporting the right infrastructures for our CaReMe approach, to grow belief in our sciences.

In a CaReMe world, patients with for example type-2 diabetes could manage their disease without having to worry about their heart or kidneys. In a CaReMe world, we aspire to bring peace of mind to patients, physicians and caretakers.

Our mission is to care for the CVRM patient, as one, considering all co-morbidities. With the CaReMe approach, we create a world of close, collaborative care for patients, while also working hand in hand with healthcare professionals to ensure that our treatments and medicines are relevant across their specialties and respond to their needs. Let’s all work together to complete the picture and treat the patient as a whole. 
 



References

1. World Health Organization. WHO World Heart Day 2017: Scale up prevention of heart attack and stroke: World Health Organization; 2017 [cited 2018

Jul 25]. Available from: URL: http://www.who.int/cardiovascular_diseases/world-heart-day-2017/en/.

2. Wang H et al. Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980–2015:

A systematic analysis for the Global Burden of Disease Study 2015. The Lancet 2016; 388(10053):1459–544.

3. Ogurtsova K et al. IDF Diabetes Atlas: Global estimates for the prevalence of diabetes for 2015 and 2040. Diabetes Res Clin Pract 2017; 128:40–50.

4. Centers for Disease Control and Prevention (CDC). National Diabetes Statistics Report, 2014: Centers for Disease Control and Preventions Division of

Diabetes Translation [cited 2018 Jul 25]. Available from: URL: https://www.cdc.gov/diabetes/pdfs/data/2014-report-estimates-of-diabetes-and-its-burden-

in-the-united-states.pdf.

5. McMahon GM et al. Mid-adulthood risk factor profiles for CKD. J Am Soc Nephrol 2014; 25(11):2633–41.

Veeva ID: Z4-12807.
Date of next review: September 2020